453 related articles for article (PubMed ID: 12729340)
1. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis.
Shin SS; Hyson AM; Castañeda C; Sánchez E; Alcántara F; Mitnick CD; Fawzi MC; Bayona J; Farmer PE; Kim JY; Furin JJ
Int J Tuberc Lung Dis; 2003 Apr; 7(4):347-53. PubMed ID: 12729340
[TBL] [Abstract][Full Text] [Related]
2. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis.
Vega P; Sweetland A; Acha J; Castillo H; Guerra D; Smith Fawzi MC; Shin S
Int J Tuberc Lung Dis; 2004 Jun; 8(6):749-59. PubMed ID: 15182146
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis.
Furin JJ; Mitnick CD; Shin SS; Bayona J; Becerra MC; Singler JM; Alcantara F; Castañieda C; Sanchez E; Acha J; Farmer PE; Kim JY
Int J Tuberc Lung Dis; 2001 Jul; 5(7):648-55. PubMed ID: 11467371
[TBL] [Abstract][Full Text] [Related]
4. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.
Chavez Pachas AM; Blank R; Smith Fawzi MC; Bayona J; Becerra MC; Mitnick CD
Int J Tuberc Lung Dis; 2004 Jan; 8(1):52-8. PubMed ID: 14974746
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.
von der Lippe B; Sandven P; Brubakk O
J Infect; 2006 Feb; 52(2):92-6. PubMed ID: 15907341
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
[TBL] [Abstract][Full Text] [Related]
7. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
[TBL] [Abstract][Full Text] [Related]
8. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis.
Bayona J; Chavez-Pachas AM; Palacios E; Llaro K; Sapag R; Becerra MC
Int J Tuberc Lung Dis; 2003 Dec; 7(12 Suppl 3):S501-9. PubMed ID: 14677844
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
10. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
[TBL] [Abstract][Full Text] [Related]
11. Linezolid in the treatment of multidrug-resistant tuberculosis.
Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
[TBL] [Abstract][Full Text] [Related]
12. Retreatment management strategies when first-line tuberculosis therapy fails.
Saravia JC; Appleton SC; Rich ML; Sarria tM; Bayona J; Becerra MC
Int J Tuberc Lung Dis; 2005 Apr; 9(4):421-9. PubMed ID: 15830748
[TBL] [Abstract][Full Text] [Related]
13. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
16. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.
Van Deun A; Salim MA; Das AP; Bastian I; Portaels F
Int J Tuberc Lung Dis; 2004 May; 8(5):560-7. PubMed ID: 15137531
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran.
Tabarsi P; Nooraki A; Mirsaeidi M; Amiri M; Baghaei P; Farnia P; Kazempour M; Heidarnazhad H; Alipanah N; Mansouri D; Masjedi MR
Respirology; 2008 Jan; 13(1):108-11. PubMed ID: 18197919
[TBL] [Abstract][Full Text] [Related]
19. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic.
Kim HJ; Hong YP; Kim SJ; Lew WJ; Lee EG
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1129-36. PubMed ID: 11769771
[TBL] [Abstract][Full Text] [Related]
20. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis.
Törün T; Tahaoğlu K; Ozmen I; Sevim T; Ataç G; Kir A; Güngör G; Bölükbaşi Y; Maden E
Int J Tuberc Lung Dis; 2007 Sep; 11(9):979-85. PubMed ID: 17705975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
